Establishing a Place in Therapy for Biosimilars in Oncology

**This is a provider education event, but may still be of interest to people living with MBC

Biosimilars provide an important opportunity in cost-savings and increased access to treatments for cancer care in the U.S. However, there is a lack of education on biosimilar safety, efficacy, extrapolation of data, and interchangeability status for pharmacists. Clinical oncology pharmacists have the opportunity to provide education on biosimilars and be a part of the multi-disciplinary decision-making process for incorporating biosimilars into practice sites. In addition, pharmacists will need training on reporting post-marketing surveillance data regarding immunogenicity, product variability and drift of biosimilars as use becomes widespread.